Novo Nordisk Ends Heartseed Cell Therapy Partnership for Heart Failure
Novo Nordisk has ended its four-year collaboration with Heartseed, terminating a partnership focused on an investigational cell therapy for heart failure. The termination is part of Novo Nordisk's strategic realignment towards its core businesses of diabetes and obesity.
The partnership, initiated in June 2021, saw Novo Nordisk invest $55 million upfront and commit to $540 million in milestone payments. Under the agreement, Novo Nordisk gained exclusive rights to advance, manufacture, and commercialize Heartseed's lead asset HS-001 outside Japan. However, the contract was formally ended in 2025.
Following the termination, Heartseed will no longer be eligible for milestone payments. All intellectual property related to HS-001 will return to Heartseed, allowing the company to explore new partnerships for the overseas development of the asset. Heartseed, meanwhile, will focus its efforts on HS-001's Japanese development using its existing funds.
The termination comes as Novo Nordisk undergoes a broader restructuring initiative, including a recent executive shuffle and plans to lay off 9,000 employees worldwide. Despite the end of this partnership, Heartseed remains committed to advancing HS-001's development in Japan and exploring new collaborations for overseas markets.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
